A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients

A Phase III study comparing Mesutoclax + azacitidine versus venetoclax + azacitidine in newly diagnosed acute myeloid leukemia (AML) patients

Trial Details

NCT ID
NCT07925190
Phase
PHASE3
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Mesutoclax (ICP-248)
  • Azacitidine (AZA)
  • Venetoclax
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Study participants with newly diagnosed AML (excluding acute promyelocytic leukemia \[APL\]) confirmed per the 2022 World Health Organization (WHO)…
  • Age ≥65 years; or age ≥18 years and \<65 years and ineligible for intensive chemotherapy.
  • The participant is expected to have a survival time of at least 12 weeks.
  • For participants aged ≥65 years: ECOG Performance Status (PS) 0-2; for participants aged ≥18 years and \<65 years: ECOG PS 0-3.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →